The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A.
This report describes and presents some preliminary results from a prospective clinical investigation to determine the ablative effect of thiotepa (N,N',N''-triethylene phosphoramide) on superficial low-stage bladder cancer and the effectiveness of this agent in the prevention of recurrent or new tumors. In the small group of cases studied thus far, therapeutic thiotepa has destroyed superficial cancers in 33 to 36% of the cases, about the same results as those reported by others. It is too early in the study to assess the benefit from the prophylactic use of thiotepa.
D002986:Clinical Trials as Topic; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009378:Neoplasms, Multiple Primary / Q000517:prevention & control; D011182:Postoperative Care; D011446:Prospective Studies; D012075:Remission, Spontaneous; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control / Q000601:surgery
D013852:Thiotepa